Loading…
Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various n...
Saved in:
| Published in: | International journal of molecular sciences 2020-02, Vol.21 (3), p.1054 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c478t-7af6ff620f71c7f5f8a1f9b03e3d1f46ffa4d089c0257f32df27eb63e9e447bb3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c478t-7af6ff620f71c7f5f8a1f9b03e3d1f46ffa4d089c0257f32df27eb63e9e447bb3 |
| container_end_page | |
| container_issue | 3 |
| container_start_page | 1054 |
| container_title | International journal of molecular sciences |
| container_volume | 21 |
| creator | Kruse, Aaron Abdel-Azim, Nour Kim, Hye Na Ruan, Yongsheng Phan, Valerie Ogana, Heather Wang, William Lee, Rachel Gang, Eun Ji Khazal, Sajad Kim, Yong-Mi |
| description | Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various new diagnostic platforms, including next-generation sequencing (NGS), has introduced significant advances in the sensitivity of MRD diagnostics. Here, we review current methods to diagnose MRD through phenotypic marker patterns or differential gene patterns through analysis by flow cytometry (FCM), polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (RQ-PCR), reverse transcription polymerase chain reaction (RT-PCR) or NGS. Future advances in clinical procedures will be molded by practical feasibility and patient needs regarding greater diagnostic sensitivity. |
| doi_str_mv | 10.3390/ijms21031054 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_52afd54b97bf4646b296837c3170cf84</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_52afd54b97bf4646b296837c3170cf84</doaj_id><sourcerecordid>2352654926</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-7af6ff620f71c7f5f8a1f9b03e3d1f46ffa4d089c0257f32df27eb63e9e447bb3</originalsourceid><addsrcrecordid>eNpdkU1rFTEUhoMotlZ3rmXAjQuvTXLyMbMRaqtt4Yogug5J5qTNdWZyTWaE_ntTby23XeWQ8_DwJi8hrxn9ANDR47gZC2cUGJXiCTlkgvMVpUo_3ZsPyItSNpRy4LJ7Tg6AUwAhxCH59DVOcbRD8x1L7Jc6nMWCtmBzhjP6OaapiVNz4pcZm_XNuL1ObrBljr5Z4_ILx2hfkmfBDgVf3Z1H5OeXzz9OL1brb-eXpyfrlRe6nVfaBhWC4jRo5nWQobUsdI4CQs-CqDsretp2nnKpA_A-cI1OAXYohHYOjsjlztsnuzHbXGPnG5NsNP8uUr4yNtdgAxrJbeilcJ121SyU451qQXtgmvrQiur6uHNtFzdi73Gasx0eSB9upnhtrtIfoylokKoK3t0Jcvq9YJnNGIvHYbATpqUYDpIrKTp-i759hG7Skqf6VYZL0WqqJLBKvd9RPqdSMob7MIya26LNftEVf7P_gHv4f7PwF_L_o6I</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548706531</pqid></control><display><type>article</type><title>Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Kruse, Aaron ; Abdel-Azim, Nour ; Kim, Hye Na ; Ruan, Yongsheng ; Phan, Valerie ; Ogana, Heather ; Wang, William ; Lee, Rachel ; Gang, Eun Ji ; Khazal, Sajad ; Kim, Yong-Mi</creator><creatorcontrib>Kruse, Aaron ; Abdel-Azim, Nour ; Kim, Hye Na ; Ruan, Yongsheng ; Phan, Valerie ; Ogana, Heather ; Wang, William ; Lee, Rachel ; Gang, Eun Ji ; Khazal, Sajad ; Kim, Yong-Mi</creatorcontrib><description>Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various new diagnostic platforms, including next-generation sequencing (NGS), has introduced significant advances in the sensitivity of MRD diagnostics. Here, we review current methods to diagnose MRD through phenotypic marker patterns or differential gene patterns through analysis by flow cytometry (FCM), polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (RQ-PCR), reverse transcription polymerase chain reaction (RT-PCR) or NGS. Future advances in clinical procedures will be molded by practical feasibility and patient needs regarding greater diagnostic sensitivity.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms21031054</identifier><identifier>PMID: 32033444</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acute lymphoblastic leukemia ; Antigens ; b-cell acute lymphoblastic leukemia ; Bone marrow ; Cardiomyopathy ; Chemotherapy ; Diagnostic systems ; Flow Cytometry ; Gene expression ; High-Throughput Nucleotide Sequencing ; Humans ; Kinases ; Leukemia ; Lymphatic leukemia ; Lymphocytes ; Medical prognosis ; Minimal residual disease ; Mutation ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - genetics ; Neoplasm, Residual - diagnosis ; Neoplasm, Residual - genetics ; Neoplastic Cells, Circulating - pathology ; Neuropsychology ; Next-generation sequencing ; Patients ; Polymerase Chain Reaction ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Radiation therapy ; Reverse transcription ; Review ; Sensitivity ; Stem cells ; t-cell acute lymphoblastic leukemia ; Transcription factors</subject><ispartof>International journal of molecular sciences, 2020-02, Vol.21 (3), p.1054</ispartof><rights>2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-7af6ff620f71c7f5f8a1f9b03e3d1f46ffa4d089c0257f32df27eb63e9e447bb3</citedby><cites>FETCH-LOGICAL-c478t-7af6ff620f71c7f5f8a1f9b03e3d1f46ffa4d089c0257f32df27eb63e9e447bb3</cites><orcidid>0000-0001-8679-0389 ; 0000-0002-3731-608X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2548706531/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2548706531?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32033444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kruse, Aaron</creatorcontrib><creatorcontrib>Abdel-Azim, Nour</creatorcontrib><creatorcontrib>Kim, Hye Na</creatorcontrib><creatorcontrib>Ruan, Yongsheng</creatorcontrib><creatorcontrib>Phan, Valerie</creatorcontrib><creatorcontrib>Ogana, Heather</creatorcontrib><creatorcontrib>Wang, William</creatorcontrib><creatorcontrib>Lee, Rachel</creatorcontrib><creatorcontrib>Gang, Eun Ji</creatorcontrib><creatorcontrib>Khazal, Sajad</creatorcontrib><creatorcontrib>Kim, Yong-Mi</creatorcontrib><title>Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various new diagnostic platforms, including next-generation sequencing (NGS), has introduced significant advances in the sensitivity of MRD diagnostics. Here, we review current methods to diagnose MRD through phenotypic marker patterns or differential gene patterns through analysis by flow cytometry (FCM), polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (RQ-PCR), reverse transcription polymerase chain reaction (RT-PCR) or NGS. Future advances in clinical procedures will be molded by practical feasibility and patient needs regarding greater diagnostic sensitivity.</description><subject>Acute lymphoblastic leukemia</subject><subject>Antigens</subject><subject>b-cell acute lymphoblastic leukemia</subject><subject>Bone marrow</subject><subject>Cardiomyopathy</subject><subject>Chemotherapy</subject><subject>Diagnostic systems</subject><subject>Flow Cytometry</subject><subject>Gene expression</subject><subject>High-Throughput Nucleotide Sequencing</subject><subject>Humans</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes</subject><subject>Medical prognosis</subject><subject>Minimal residual disease</subject><subject>Mutation</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm, Residual - diagnosis</subject><subject>Neoplasm, Residual - genetics</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Neuropsychology</subject><subject>Next-generation sequencing</subject><subject>Patients</subject><subject>Polymerase Chain Reaction</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Radiation therapy</subject><subject>Reverse transcription</subject><subject>Review</subject><subject>Sensitivity</subject><subject>Stem cells</subject><subject>t-cell acute lymphoblastic leukemia</subject><subject>Transcription factors</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkU1rFTEUhoMotlZ3rmXAjQuvTXLyMbMRaqtt4Yogug5J5qTNdWZyTWaE_ntTby23XeWQ8_DwJi8hrxn9ANDR47gZC2cUGJXiCTlkgvMVpUo_3ZsPyItSNpRy4LJ7Tg6AUwAhxCH59DVOcbRD8x1L7Jc6nMWCtmBzhjP6OaapiVNz4pcZm_XNuL1ObrBljr5Z4_ILx2hfkmfBDgVf3Z1H5OeXzz9OL1brb-eXpyfrlRe6nVfaBhWC4jRo5nWQobUsdI4CQs-CqDsretp2nnKpA_A-cI1OAXYohHYOjsjlztsnuzHbXGPnG5NsNP8uUr4yNtdgAxrJbeilcJ121SyU451qQXtgmvrQiur6uHNtFzdi73Gasx0eSB9upnhtrtIfoylokKoK3t0Jcvq9YJnNGIvHYbATpqUYDpIrKTp-i759hG7Skqf6VYZL0WqqJLBKvd9RPqdSMob7MIya26LNftEVf7P_gHv4f7PwF_L_o6I</recordid><startdate>20200205</startdate><enddate>20200205</enddate><creator>Kruse, Aaron</creator><creator>Abdel-Azim, Nour</creator><creator>Kim, Hye Na</creator><creator>Ruan, Yongsheng</creator><creator>Phan, Valerie</creator><creator>Ogana, Heather</creator><creator>Wang, William</creator><creator>Lee, Rachel</creator><creator>Gang, Eun Ji</creator><creator>Khazal, Sajad</creator><creator>Kim, Yong-Mi</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8679-0389</orcidid><orcidid>https://orcid.org/0000-0002-3731-608X</orcidid></search><sort><creationdate>20200205</creationdate><title>Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia</title><author>Kruse, Aaron ; Abdel-Azim, Nour ; Kim, Hye Na ; Ruan, Yongsheng ; Phan, Valerie ; Ogana, Heather ; Wang, William ; Lee, Rachel ; Gang, Eun Ji ; Khazal, Sajad ; Kim, Yong-Mi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-7af6ff620f71c7f5f8a1f9b03e3d1f46ffa4d089c0257f32df27eb63e9e447bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Antigens</topic><topic>b-cell acute lymphoblastic leukemia</topic><topic>Bone marrow</topic><topic>Cardiomyopathy</topic><topic>Chemotherapy</topic><topic>Diagnostic systems</topic><topic>Flow Cytometry</topic><topic>Gene expression</topic><topic>High-Throughput Nucleotide Sequencing</topic><topic>Humans</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes</topic><topic>Medical prognosis</topic><topic>Minimal residual disease</topic><topic>Mutation</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm, Residual - diagnosis</topic><topic>Neoplasm, Residual - genetics</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Neuropsychology</topic><topic>Next-generation sequencing</topic><topic>Patients</topic><topic>Polymerase Chain Reaction</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Radiation therapy</topic><topic>Reverse transcription</topic><topic>Review</topic><topic>Sensitivity</topic><topic>Stem cells</topic><topic>t-cell acute lymphoblastic leukemia</topic><topic>Transcription factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kruse, Aaron</creatorcontrib><creatorcontrib>Abdel-Azim, Nour</creatorcontrib><creatorcontrib>Kim, Hye Na</creatorcontrib><creatorcontrib>Ruan, Yongsheng</creatorcontrib><creatorcontrib>Phan, Valerie</creatorcontrib><creatorcontrib>Ogana, Heather</creatorcontrib><creatorcontrib>Wang, William</creatorcontrib><creatorcontrib>Lee, Rachel</creatorcontrib><creatorcontrib>Gang, Eun Ji</creatorcontrib><creatorcontrib>Khazal, Sajad</creatorcontrib><creatorcontrib>Kim, Yong-Mi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kruse, Aaron</au><au>Abdel-Azim, Nour</au><au>Kim, Hye Na</au><au>Ruan, Yongsheng</au><au>Phan, Valerie</au><au>Ogana, Heather</au><au>Wang, William</au><au>Lee, Rachel</au><au>Gang, Eun Ji</au><au>Khazal, Sajad</au><au>Kim, Yong-Mi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2020-02-05</date><risdate>2020</risdate><volume>21</volume><issue>3</issue><spage>1054</spage><pages>1054-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Minimal residual disease (MRD) refers to a chemotherapy/radiotherapy-surviving leukemia cell population that gives rise to relapse of the disease. The detection of MRD is critical for predicting the outcome and for selecting the intensity of further treatment strategies. The development of various new diagnostic platforms, including next-generation sequencing (NGS), has introduced significant advances in the sensitivity of MRD diagnostics. Here, we review current methods to diagnose MRD through phenotypic marker patterns or differential gene patterns through analysis by flow cytometry (FCM), polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (RQ-PCR), reverse transcription polymerase chain reaction (RT-PCR) or NGS. Future advances in clinical procedures will be molded by practical feasibility and patient needs regarding greater diagnostic sensitivity.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>32033444</pmid><doi>10.3390/ijms21031054</doi><orcidid>https://orcid.org/0000-0001-8679-0389</orcidid><orcidid>https://orcid.org/0000-0002-3731-608X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2020-02, Vol.21 (3), p.1054 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_52afd54b97bf4646b296837c3170cf84 |
| source | Publicly Available Content (ProQuest); PubMed Central |
| subjects | Acute lymphoblastic leukemia Antigens b-cell acute lymphoblastic leukemia Bone marrow Cardiomyopathy Chemotherapy Diagnostic systems Flow Cytometry Gene expression High-Throughput Nucleotide Sequencing Humans Kinases Leukemia Lymphatic leukemia Lymphocytes Medical prognosis Minimal residual disease Mutation Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - genetics Neoplasm, Residual - diagnosis Neoplasm, Residual - genetics Neoplastic Cells, Circulating - pathology Neuropsychology Next-generation sequencing Patients Polymerase Chain Reaction Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Radiation therapy Reverse transcription Review Sensitivity Stem cells t-cell acute lymphoblastic leukemia Transcription factors |
| title | Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T01%3A13%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Minimal%20Residual%20Disease%20Detection%20in%20Acute%20Lymphoblastic%20Leukemia&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Kruse,%20Aaron&rft.date=2020-02-05&rft.volume=21&rft.issue=3&rft.spage=1054&rft.pages=1054-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms21031054&rft_dat=%3Cproquest_doaj_%3E2352654926%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-7af6ff620f71c7f5f8a1f9b03e3d1f46ffa4d089c0257f32df27eb63e9e447bb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2548706531&rft_id=info:pmid/32033444&rfr_iscdi=true |